Presentation is loading. Please wait.

Presentation is loading. Please wait.

Cost-Effectiveness Analysis of New HCV Treatments in Egyptian Cirrhotic and Non- Cirrhotic Patients: A Societal Perspective  Gihan Hamdy Elsisi, MSc, PhD,

Published byΜακάριος Ἱερεμίας Λούλης Modified over 6 years ago

Similar presentations

Presentation on theme: "Cost-Effectiveness Analysis of New HCV Treatments in Egyptian Cirrhotic and Non- Cirrhotic Patients: A Societal Perspective  Gihan Hamdy Elsisi, MSc, PhD,"— Presentation transcript:

1 Cost-Effectiveness Analysis of New HCV Treatments in Egyptian Cirrhotic and Non- Cirrhotic Patients: A Societal Perspective  Gihan Hamdy Elsisi, MSc, PhD, Asmaa Aburawash, BSc, Emam Waked, MD  Value in Health Regional Issues  Volume 13, Pages 7-15 (September 2017) DOI: /j.vhri Copyright © Terms and Conditions

2 Fig. 1 Markov process model for noncirrhotic patients. DCC, decompensated cirrhosis; F3, METAVIR fibrosis score F3; F4, METAVIR fibrosis score F4; HCC, hepatocellular carcinoma; LT, liver transplant. Value in Health Regional Issues  , 7-15DOI: ( /j.vhri ) Copyright © Terms and Conditions

3 Fig. 2 Markov process model for cirrhotic patients. DCC, decompensated cirrhosis; F4, METAVIR fibrosis score F4; HCC, hepatocellular carcinoma; LT, liver transplant. Value in Health Regional Issues  , 7-15DOI: ( /j.vhri ) Copyright © Terms and Conditions

4 Fig. 3 Results of one-way sensitivity analysis for noncirrhotic patients. (A) SOF + DCV vs. SOF + pegIFN + RBV. (B) SOF + LDV + RBV vs. SOF + pegIFN + RBV. (C) SOF + RBV vs. SOF + pegIFN + RBV. DCV, daclatasvir; HCC, hepatocellular carcinoma; LDV, ledipasvir; pegIFN, pegylated interferon alfa; QALY, quality-adjusted life-year; RBV, ribavirin; SOF, sofosbuvir; SVR, sustained virological response. Value in Health Regional Issues  , 7-15DOI: ( /j.vhri ) Copyright © Terms and Conditions

5 Fig. 4 Results of one-way sensitivity analysis for cirrhotic patients. (A) SOF + DCV vs. SOF + pegIFN + RBV. (B) SOF + LDV + RBV vs. SOF + pegIFN + RBV. (C) SOF + RBV vs. SOF + pegIFN + RBV. DCC, decompensated cirrhosis; DCV, daclatasvir; HCC, hepatocellular carcinoma; LDV, ledipasvir; pegIFN, pegylated interferon alfa; QALY, quality-adjusted life-year; RBV, ribavirin; SOF, sofosbuvir; SVR, sustained virological response. Value in Health Regional Issues  , 7-15DOI: ( /j.vhri ) Copyright © Terms and Conditions

6 Fig. 5 Incremental cost-effectiveness plane for SOF + DCV vs. SOF + pegIFN + RBV in noncirrhotic patients. DCV, daclatasvir; pegIFN, pegylated interferon alfa; RBV, ribavirin; SOF, sofosbuvir. Value in Health Regional Issues  , 7-15DOI: ( /j.vhri ) Copyright © Terms and Conditions

Download ppt "Cost-Effectiveness Analysis of New HCV Treatments in Egyptian Cirrhotic and Non- Cirrhotic Patients: A Societal Perspective  Gihan Hamdy Elsisi, MSc, PhD,"

Similar presentations

Hepatitis web study Hepatitis web study Ledipasvir-Sofosbuvir + Ribavirin in HCV GT 1,4 SOLAR-1 (Post Transplant) Phase 2 Treatment Naïve and Treatment.

Hepatitis web study Hepatitis web study Ledipasvir-Sofosbuvir + Ribavirin in HCV GT 1,4 SOLAR-1 (Post Transplant) Phase 2 Treatment Naïve and Treatment.
Hepatitis web study Hepatitis web study Ledipasvir-Sofosbuvir for 8 or 12 weeks in HCV GT1 ION-3 Phase 3 Treatment Naïve Kowdley K, et al. N Engl J Med.

Hepatitis web study Hepatitis web study Ledipasvir-Sofosbuvir for 8 or 12 weeks in HCV GT1 ION-3 Phase 3 Treatment Naïve Kowdley K, et al. N Engl J Med.
Hepatitis web study Hepatitis web study Daclatasvir + Sofosbuvir +/- Ribavirin in Genotypes 1-3 A1444-040 Trial Phase 2a Treatment Naïve and Treatment.

Hepatitis web study Hepatitis web study Daclatasvir + Sofosbuvir +/- Ribavirin in Genotypes 1-3 A Trial Phase 2a Treatment Naïve and Treatment.
#LJWG2015 HEPATITIS C IN PEOPLE WHO USE DRUGS Improving Care for Hepatitis C: A Framework Approach LONDON 2015.

#LJWG2015 HEPATITIS C IN PEOPLE WHO USE DRUGS Improving Care for Hepatitis C: A Framework Approach LONDON 2015.
Hepatitis web study Hepatitis web study Daclatasvir + Sofosbuvir +/- Ribavirin in Genotype 1-3 AI444040 Trial Phase 2a Treatment-Naïve and Treatment-Experienced.

Hepatitis web study Hepatitis web study Daclatasvir + Sofosbuvir +/- Ribavirin in Genotype 1-3 AI Trial Phase 2a Treatment-Naïve and Treatment-Experienced.
Date of download: 6/1/2016 From: Cost-Effectiveness of Novel Regimens for the Treatment of Hepatitis C Virus Ann Intern Med. 2015;162(6):407-419. doi:10.7326/M14-1152.

Date of download: 6/1/2016 From: Cost-Effectiveness of Novel Regimens for the Treatment of Hepatitis C Virus Ann Intern Med. 2015;162(6): doi: /M
Date of download: 6/2/2016 From: New Protease Inhibitors for the Treatment of Chronic Hepatitis C: A Cost-Effectiveness Analysis Ann Intern Med. 2012;156(4):279-290.

Date of download: 6/2/2016 From: New Protease Inhibitors for the Treatment of Chronic Hepatitis C: A Cost-Effectiveness Analysis Ann Intern Med. 2012;156(4):
Date of download: 6/25/2016 From: Interferon Therapy Reduces the Risk for Hepatocellular Carcinoma: National Surveillance Program of Cirrhotic and Noncirrhotic.

Date of download: 6/25/2016 From: Interferon Therapy Reduces the Risk for Hepatocellular Carcinoma: National Surveillance Program of Cirrhotic and Noncirrhotic.
Date of download: 9/17/2016 From: The Changing Burden of Hepatitis C Virus Infection in the United States: Model-Based Predictions Ann Intern Med. 2014;161(3):170-180.

Date of download: 9/17/2016 From: The Changing Burden of Hepatitis C Virus Infection in the United States: Model-Based Predictions Ann Intern Med. 2014;161(3):
EASL Recommendations on Treatment of Hepatitis C 2015 Treatment recommendations for HCV-monoinfected or HCV/HIV coinfected patients with chronic hepatitis.

EASL Recommendations on Treatment of Hepatitis C 2015 Treatment recommendations for HCV-monoinfected or HCV/HIV coinfected patients with chronic hepatitis.
Value in Health Regional Issues

Value in Health Regional Issues
Volume 16, Issue 6, Pages (September 2013)

Volume 16, Issue 6, Pages (September 2013)
Daclatasvir + Sofosbuvir +/- Ribavirin in Genotype 1-3 Trial

Daclatasvir + Sofosbuvir +/- Ribavirin in Genotype 1-3 Trial
129 patients with chronic hepatitis C

129 patients with chronic hepatitis C
Design Randomisation 1 : 1 Open-label W16 W24 > 18 years

Design Randomisation 1 : 1 Open-label W16 W24 > 18 years
Phase 3 Treatment-Naïve and Treatment-Experienced

Phase 3 Treatment-Naïve and Treatment-Experienced
HCV Studies Performed on New Iranian DAA Drugs

HCV Studies Performed on New Iranian DAA Drugs
Cost-effectiveness Analysis of Viscosupplementation versus Conventional Supportive Therapy for Knee Osteoarthritis in Colombia  Juan-Carlos Castro, MD,

Cost-effectiveness Analysis of Viscosupplementation versus Conventional Supportive Therapy for Knee Osteoarthritis in Colombia  Juan-Carlos Castro, MD,
Which patients with genotype 1 chronic hepatitis C can benefit from prolonged treatment with the ‘accordion’ regimen?  Patrick Marcellin, E. Jenny Heathcote,

Which patients with genotype 1 chronic hepatitis C can benefit from prolonged treatment with the ‘accordion’ regimen?  Patrick Marcellin, E. Jenny Heathcote,
Direct-Acting Antiviral Agents for Patients With Hepatitis C Virus Genotype 1 Infection Are Cost-Saving  Jagpreet Chhatwal, Tianhua He, Chin Hur, Maria.

Direct-Acting Antiviral Agents for Patients With Hepatitis C Virus Genotype 1 Infection Are Cost-Saving  Jagpreet Chhatwal, Tianhua He, Chin Hur, Maria.

Similar presentations

Ads by Google